Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843531 · ClinicalTrials.gov registry record · Phase 2
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00843531 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 17 participants.
The verdict
NCT00843531, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
Interventions
- DRUG RAD001
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-06-25 |
| Est. Completion | 2016-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00843531
The ClinicalTrials.gov registry entry for NCT00843531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RAD001 is the first listed.
NCT00843531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00843531 about?
NCT00843531 is a clinical study titled "RAD001 and Erlotinib in Patients With Neuroendocrine Tumors". The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
What is the current status of trial NCT00843531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-06-25. Estimated completion is 2016-08-20.
What interventions are being tested in trial NCT00843531?
The interventions under investigation include: RAD001 (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT00843531?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.